Patients and donors: transplantation procedure
| Characteristic . | Value . |
|---|---|
| Patients included in the analysis of transplantation rates | |
| N | 16 403 |
| Median patient age, y (range) | 41.6 (18-78) |
| Median year of transplantation (range) | 2003 (2001-2005) |
| Diagnosis | |
| AML | 11 504 (70%) |
| ALL | 4496 (27%) |
| Acute undifferentiated leukemia | 84 (1%) |
| Acute biphenotypic leukemia | 178 (1%) |
| Other/unknown | 141 (1%) |
| Disease status at HSCT | |
| CR1 | 9216 (56%) |
| CR2 | 2611 (16%) |
| CR3 or more advanced | 3379 (21%) |
| Unknown | 1197 (7%) |
| Type of HSCT | |
| Autologous | 4641 (28%) |
| Syngeneic | 69 (0.4%) |
| Allogeneic | 11 693 (71%) |
| HLA-identical sibling | 6279 |
| Matched other related | 219 |
| Matched unrelated | 3366 |
| Mismatched relative | 578 |
| Mismatched unrelated | 1154 |
| Other/unknown | 97 |
| Chronologic number of HSCT for these patients | |
| First | 9216 (56%) |
| Second or subsequent | 7187 (44%) |
| Patients included in the analysis of transplantation outcome | |
| N | 2015 |
| Median patient age, y (range) | 40.1 (18-70) |
| Median year of transplantation (range) | 2003 (2001-2005) |
| Donor/recipient sex | |
| Female/male | 379 (19%) |
| Other combinations | 1607 (80%) |
| Unknown | 29 (1%) |
| Median interval from diagnosis to transplantation, d (range) | 149 (40-673) |
| Donor type | |
| HLA-identical sibling | 1583 (79%) |
| HLA-matched unrelated | 432 (21%) |
| Type of conditioning | |
| Chemotherapy-based | 972 (48%) |
| Total body irradiation-based | 1040 (52%) |
| Unknown | 3 |
| Source of stem cells | |
| Bone marrow | 696 (35%) |
| Peripheral blood | 1310 (65%) |
| Bone marrow and peripheral blood | 9 |
| Characteristic . | Value . |
|---|---|
| Patients included in the analysis of transplantation rates | |
| N | 16 403 |
| Median patient age, y (range) | 41.6 (18-78) |
| Median year of transplantation (range) | 2003 (2001-2005) |
| Diagnosis | |
| AML | 11 504 (70%) |
| ALL | 4496 (27%) |
| Acute undifferentiated leukemia | 84 (1%) |
| Acute biphenotypic leukemia | 178 (1%) |
| Other/unknown | 141 (1%) |
| Disease status at HSCT | |
| CR1 | 9216 (56%) |
| CR2 | 2611 (16%) |
| CR3 or more advanced | 3379 (21%) |
| Unknown | 1197 (7%) |
| Type of HSCT | |
| Autologous | 4641 (28%) |
| Syngeneic | 69 (0.4%) |
| Allogeneic | 11 693 (71%) |
| HLA-identical sibling | 6279 |
| Matched other related | 219 |
| Matched unrelated | 3366 |
| Mismatched relative | 578 |
| Mismatched unrelated | 1154 |
| Other/unknown | 97 |
| Chronologic number of HSCT for these patients | |
| First | 9216 (56%) |
| Second or subsequent | 7187 (44%) |
| Patients included in the analysis of transplantation outcome | |
| N | 2015 |
| Median patient age, y (range) | 40.1 (18-70) |
| Median year of transplantation (range) | 2003 (2001-2005) |
| Donor/recipient sex | |
| Female/male | 379 (19%) |
| Other combinations | 1607 (80%) |
| Unknown | 29 (1%) |
| Median interval from diagnosis to transplantation, d (range) | 149 (40-673) |
| Donor type | |
| HLA-identical sibling | 1583 (79%) |
| HLA-matched unrelated | 432 (21%) |
| Type of conditioning | |
| Chemotherapy-based | 972 (48%) |
| Total body irradiation-based | 1040 (52%) |
| Unknown | 3 |
| Source of stem cells | |
| Bone marrow | 696 (35%) |
| Peripheral blood | 1310 (65%) |
| Bone marrow and peripheral blood | 9 |
CR indicates complete remission.